ChroMedX Collaborates with Biointerface Institute and Receives Grant

TORONTO, ONTARIO -- (September 16, 2015) - ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has entered into a collaboration with Dr. Leyla Soleymani of the Biointerface Institute of McMaster University and received an Engage Grant from NSERC (Natural Sciences and Engineering Research Council of Canada) to further HemoPalmTM biosensor development.

Dr. Soleyemani’s work will focus on novel biosensor technology which has the potential to both reduce the cost of the HemoPalmTM biosensors as well as broaden the scope of the types of analytes which can be measured.

The McMaster and ChroMedX partnership has been awarded an NSERC Engage Grant which is funded by NSERC (Natural Sciences and Engineering Research Council of Canada).

“We are pleased to be working with Dr. Soleymani on this project.  Her novel approach to sensor technology holds great promise for us.  In addition this relationship with the Biointerface Institute broadens and enhances an already significant relationship with McMaster University. We also thank NSERC for awarding this grant which will be of benefit to the development of Canadian medical technology“

Dr. Leyla Soleymani is an Associate Professor in the Department of Engineering Physics .  Her specific area of research is the development of biosensors for Point-of-care applications.  Her sensors feature high surface area which has the potential to enhance response and accuracy of the HemoPalmTM system.

“I am excited to be working with the ChroMedX team on their novel HemoPalmTM Point-of-care system” said Dr. Soleymani, Assistant Professor, Biointerfaces Institute, McMaster University

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Facebook: facebook.com/ChroMedXcorp
Twitter: www.twitter.com/ChroMedXcorp

Investor Relations:

Shawn Overton
d. 647-528-9344
o. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
soverton@ChroMedX.com

 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.